Lineage Financial Statements From 2010 to 2024
| BTX Stock | ILS 212.90 8.70 3.93% |
Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as , as well as many indicators such as . Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.
Lineage |
Lineage Cell Therapeutics Company Gross Profit Analysis
Lineage Cell's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Lineage Cell Gross Profit | 4.69 M |
Most of Lineage Cell's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lineage Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Lineage Cell Therapeutics reported 4.69 M of gross profit. This is 99.79% lower than that of the Healthcare sector and 99.51% lower than that of the Biotechnology industry. The gross profit for all Israel stocks is 99.98% higher than that of the company.
Lineage Cell Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lineage Cell's current stock value. Our valuation model uses many indicators to compare Lineage Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lineage Cell competition to find correlations between indicators driving Lineage Cell's intrinsic value. More Info.Lineage Cell Therapeutics is number one stock in price to book category among its peers. It also is number one stock in price to sales category among its peers fabricating about 34.33 of Price To Sales per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Lineage Cell by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lineage Cell's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Lineage Cell Financial Statements
Lineage Cell stakeholders use historical fundamental indicators, such as Lineage Cell's revenue or net income, to determine how well the company is positioned to perform in the future. Although Lineage Cell investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lineage Cell's assets and liabilities are reflected in the revenues and expenses on Lineage Cell's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lineage Cell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out the analysis of Lineage Cell Correlation against competitors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.